Clinical Management of Episodic Memory Changes in Dementia
- 315 Downloads
Purpose of review
The purpose of this review was to discuss therapeutic options available for the treatment of memory difficulties in dementia.
Because of the lack of progress in the availability of new medications, there has been an increased interest in focusing on non-pharmacological means to management cognitive symptoms related to dementia.
The clinical management of memory loss should focus both on pharmacological and non-pharmacological approaches. Treatment with medications should usually begin with a cholinesterase inhibitor and then followed by addition of memantine if there is a decline. In addition to medication management, emphasis should be placed on the importance of maintaining a healthy lifestyle that encompasses physical activities, cognitive stimulation, and a healthy diet.
KeywordsDementia Alzheimer’s disease Treatment Non-pharmacological Physical activities Mediterranean diet
Compliance with Ethical Standards
Conflict of Interest
The author declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.American Psychiatric Association, American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013.Google Scholar
- 2.Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2017. 2017;13(3):325–73.Google Scholar
- 6.Villarroya M, García AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer’s disease. Curr Pharm Des 2004;10(25):3177–3184.Google Scholar
- 7.Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.Google Scholar
- 9.Zhu CW, Livote EE, Scarmeas N, Albert M, Brandt J, Blacker D, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer’s disease. Alzheimers Dement. 2013;9(6):733–40.Google Scholar
- 11.Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009 May;24(5):479–88.Google Scholar
- 14.Alva G, Cummings JL. Relative tolerability of Alzheimer’s disease treatments. Psychiatry (Edgmont). 2008;5(11):27–36.Google Scholar
- 16.Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer’s disease. Curr Med Res Opin. 2005;21(11):1809–18.Google Scholar
- 20.McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006 19;(2):CD003154.Google Scholar
- 24.Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83–9.CrossRefPubMedGoogle Scholar
- 25.•Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6. https://doi.org/10.1186/alzrt160. eCollection 2013. This meta-analysis supports the use of combination therapy of cholinesterase inhibitor and memantine.
- 30.Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD006489. DOI: https://doi.org/10.1002/14651858.CD006489.pub4.
- 32.Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD003260. DOI: https://doi.org/10.1002/14651858.CD003260.pub2.
- 34.Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD005562. DOI: https://doi.org/10.1002/14651858.CD005562.pub2.
- 38.•Shimada H, Makizako H, Doi T, Park H, Tsutsumimoto K, Verghese J, et al. Effects of combined physical and cognitive exercises on cognition and mobility in patients with mild cognitive impairment: a randomized clinical trial. J Am Med Dir Assoc. 2017 Nov 16. pii: S1525–8610(17)30542-X. doi: https://doi.org/10.1016/j.jamda.2017.09.019. This recent randomized clinical trial demonstrated benefits of combined physical and cognitive activities in cognition in subjects with mild cognitive impairment.
- 39.Hardman RJ, Kennedy G, Macpherson H, Scholey AB, Pipingas A. Adherence to a Mediterranean-style diet and effects on cognition in adults: a qualitative evaluation and systematic review of longitudinal and prospective trials. Front Nutr. 2016;3:22. https://doi.org/10.3389/fnut.2016.00022. eCollection 2016CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Gu Y, Brickman AM, Stern Y, Habeck CG, Razlighi QR, Luchsinger JA, et al. Mediterranean diet and brain structure in a multiethnic elderly cohort. Neurology. 2015;85(20):1744–51.Google Scholar
- 44.• Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–63. https://doi.org/10.1016/S0140-6736(15)60461-5. This is one of the largest randomized controlled trial that showed a multimodal approach including diet, exercise, and cognitive stimulation could maintain or improve cognitive function in at risk subjects.CrossRefPubMedGoogle Scholar